A new fluid biomarker for Parkinson’s disease (PD) was developed, offering a high-accuracy biological classification, ...

In the European Union (EU), lecanemab is indicated for the treatment of adult patients with a clinical diagnosis of mild cognitive impairment and mild dementia due to Alzheimer’s disease (early ...

Department of Chemical Engineering and Biotechnology, University of Cambridge, Philippa Fawcett Drive, Cambridge CB3 0AS, U.K. Department of Chemistry, University of Cambridge, Cambridge CB2 1EW, U.K.

Department of Neurology, Affiliated Hospital of Zunyi Medical University, Zunyi, Guizhou, China Background: Lecanemab is a humanized murine IgG1 antibody. Recent Phase 3 clinical trials have ...

Lecanemab is the result of a strategic research alliance between BioArctic and Eisai. It is a humanized immunoglobulin gamma 1 (IgG1) monoclonal antibody directed against aggregated soluble ...

BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai today announced that the European Commission (EC) has decided to refer the marketing authorisation approval decision of lecanemab in the ...

On Wednesday, April 9, as part of Poster Session P12, “Aging, Dementia, and Behavioral Neurology: Alzheimer’s Treatment” (11:45 AM - 12:45 PM PT), two posters will be presented on real-world ...

On Wednesday, April 9, as part of Poster Session P12, "Aging, Dementia, and Behavioral Neurology: Alzheimer's Treatment" (11:45 AM - 12:45 PM PT), two posters will be presented on real-world ...

You have permission to edit this article. Edit Close Activate Subscribe My Account Logout Login/Register ...